2022年英国≥75岁人群mRNA新冠疫苗加强针相对疫苗效果:春季-夏季(单价疫苗)与秋冬季(二价疫苗)加强活动的具前瞻性检测阴性病例对照研究
该研究在≥75岁住院急性呼吸道疾病患者中开展前瞻性单中心检测阴性病例对照研究,评估2022年春季-夏季单价mRNA第四剂相对未完全加强者的rVE为46.6%(95%CI 13.9-67.1),秋冬季BA.1/原始株二价mRNA第五剂相对第四剂单价mRNA的rVE为46.7%(95%CI 18.0-65.1),两种加强针对住院均显示获益。
要点
- ≥75岁住院患者中,第四剂单价mRNA疫苗相对未完全加强者rVE为46.6%(95%CI 13.9-67.1)。
- 第五剂BA.1/原始株二价mRNA疫苗相对第四剂单价mRNA疫苗rVE为46.7%(95%CI 18.0-65.1)。
- 二价mRNA加强针对Omicron感染住院提供的保护与当年较早接种的单价mRNA加强针相似。
核心结论
- 第四剂单价mRNA和第五剂BA.1/原始株二价mRNA新冠疫苗在老年人中作为加强针均显示获益。
- 二价mRNA加强针对Omicron感染住院提供的保护与当年较早接种的单价mRNA加强针相似。
- 这些发现支持数个欧洲国家推荐使用BA.1/原始株二价加强针的免疫规划。
研究设计与样本
- 前瞻性单中心检测阴性设计病例对照研究,纳入≥75岁因COVID-19或其他急性呼吸道疾病住院者。
- 春季-夏季加强分析纳入682例对照和182例病例;秋冬季加强分析纳入572例对照和152例病例。
- 回归分析控制年龄、性别、社会经济状况、患者合并症、社区SARS-CoV-2流行率、疫苗品牌及基线剂次与住院间隔。
主要发现
- 春季-夏季加强分析中,第四剂单价mRNA新冠疫苗相对未完全加强者rVE为46.6%(95%CI 13.9-67.1)。
- 秋冬季加强分析中,第五剂二价mRNA新冠疫苗相对第四剂单价mRNA新冠疫苗rVE为46.7%(95%CI 18.0-65.1)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundUnderstanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations against SARS-CoV-2 infection is a public health priority. A precise analysis of the rVE of monovalent and bivalent boosters given during the 2022 spring-summer and autumn-winter campaigns, respectively, in a defined population remains of interest.AimWe assessed rVE against hospitalisation for the spring-summer (fourth vs third monovalent mRNA vaccine doses) and autumn-winter (fifth BA.1/ancestral bivalent vs fourth monovalent mRNA vaccine dose) boosters.MethodsWe performed a prospective single-centre test-negative design case-control study in ≥ 75-year-old people hospitalised with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling for age, sex, socioeconomic status, patient comorbidities, community SARS-CoV-2 prevalence, vaccine brand and time between baseline dose and hospitalisation.ResultsWe included 682 controls and 182 cases in the spring-summer booster analysis and 572 controls and 152 cases in the autumn-winter booster analysis. A monovalent mRNA COVID-19 vaccine as fourth dose showed 46.6% rVE (95% confidence interval (CI): 13.9-67.1) vs those not fully boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had 46.7% rVE (95% CI: 18.0-65.1), compared with a fourth monovalent mRNA COVID-19 vaccine dose.ConclusionsBoth fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offered similar protection against hospitalisation with Omicron infection to monovalent mRNA boosters given earlier in the year. These findings support immunisation programmes in several European countries that advised the use of BA.1/ancestral bivalent booster doses.
引用
- Chatzilena A, Hyams C, Challen R, et al. Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case-control study, United Kingdom, 2022. Euro Surveill. 2023. PMID: 38037728. doi:10.2807/1560-7917.ES.2023.28.48.2300173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。